AMP 201
Alternative Names: AMP-201Latest Information Update: 30 Jun 2023
At a glance
- Originator Nagoya University
- Developer Amplo Biotechnology; Nagoya University
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neuromuscular disorders
- Research Congenital myasthenic syndromes
Most Recent Events
- 29 May 2023 Nagoya University and Amplo Biotechnology signs Exclusive License Agreement to advance AMP 201 gene therapy for Neuromuscular disorders
- 29 May 2023 Early research in Congenital myasthenic syndromes in USA (unspecified route)
- 29 May 2023 Preclinical trials in Neuromuscular disorders in USA (unspecified route)